Latest News

Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner

CAMBRIDGE, England & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part of BBI Group (“BBI”), to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva. BBI Solutions is a leading global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market, with manufacturing sites in

Source link

Related posts

Here's More Evidence Obesity Can Shorten Your Life


Medical News Today: 17 reasons for always feeling hungry


IQbuds Enhanced Hearing Devices at CES 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World